New Triple-Threat treatment tested for tough kidney cancers
NCT ID NCT05501054
Summary
This study is testing whether adding a new oral drug called ciforadenant to two existing immunotherapy drugs (ipilimumab and nivolumab) can better control advanced kidney cancer. It aims to see if this three-drug combination is safe and effective for adults who have not yet received any treatment for their metastatic disease. The trial will measure how well tumors shrink and how long the cancer stays under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.